Modern day cost analysis demonstrates medical therapy as a highly cost‑effective first‑line treatment for BPH/LUTS
- 21 February 2026
- journal article
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
Abstract
Generic competition has markedly reduced the cost of medications for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), potentially reshaping the value proposition of first-line therapy. We reviewed contemporary drug pricing and health-economic evidence to evaluate the cost-effectiveness of medical therapy as initial management for BPH/LUTS. We synthesized evidence from randomized trials, meta-analyses, international guidelines, and published cost-effectiveness/cost-utility analyses comparing pharmacotherapy with common minimally invasive and surgical BPH interventions. Common generic agents (e.g., tamsulosin and finasteride) are available for approximately $2-$7 per month through discount programs. Clinical trial evidence demonstrates meaningful symptom improvement and reduced risk of progression with alpha-blockers and 5-alpha-reductase inhibitors, particularly in combination therapy. Published economic models consistently show favorable incremental cost-effectiveness ratios for medical management versus watchful waiting or surgery; under current generic pricing, medication costs rarely approach the one-time costs of procedural interventions within a typical lifespan. Contemporary clinical and economic evidence supports medical therapy as a highly cost-effective first-line treatment for BPH/LUTS, with procedural interventions best reserved for medication failure, complications, or patient preference.Keywords
This publication has 19 references indexed in Scilit:
- Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysisScientific Reports, 2024
- Retreatment rates and postprocedural complications are higher than expected after BPH surgeries: a US healthcare claims and utilization studyProstate Cancer and Prostatic Diseases, 2023
- Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trialThe Lancet Regional Health - Europe, 2023
- Summary Paper on the 2023 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract SymptomsEuropean Urology, 2023
- Long-Term Outcome of Prostatic Artery Embolization for Patients with Benign Prostatic Hyperplasia: Single-Centre Retrospective Study in 1072 Patients Over a 10-Year PeriodCardioVascular and Interventional Radiology, 2022
- Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic HyperplasiaJournal of Urology, 2021
- Prostatic Artery Embolisation Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: 2-yr Outcomes of a Randomised, Open-label, Single-centre TrialEuropean Urology, 2021
- Cost Analysis of Prostate Artery Embolization (PAE) and Transurethral Resection of the Prostate (TURP) in the Treatment of Benign Prostatic HyperplasiaCardioVascular and Interventional Radiology, 2017
- The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT StudyEuropean Urology, 2010
- The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic HyperplasiaNew England Journal of Medicine, 2003